Ligand Pharmaceuticals (LGND) Cash & Equivalents (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Cash & Equivalents data on file, last reported at $115.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 139.8% year-over-year to $115.1 million; the trailing twelve-month figure through Mar 2026 stood at $115.1 million (up 139.8% YoY), and the FY2025 full-year result was $174.9 million, up 141.92% from the prior year.
• Cash & Equivalents eased to $115.1 million in Q1 2026, from $174.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $174.9 million in Q4 2025 to a low of $4.1 million in Q3 2022.
• A 5-year average of $57.5 million and a median of $48.0 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 82.43% in 2022 and surged 491.8% in 2023, its largest moves.
• Tracing LGND's Cash & Equivalents over 5 years: stood at $45.0 million in 2022, then plunged by 49.0% to $23.0 million in 2023, then jumped by 215.01% to $72.3 million in 2024, then surged by 141.92% to $174.9 million in 2025, then sank by 34.21% to $115.1 million in 2026.
• Business Quant data shows LGND's Cash & Equivalents at $115.1 million in Q1 2026, $174.9 million in Q4 2025, and $139.4 million in Q3 2025.